Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 9651–9700 of 75565
On February 11, 2025, the Board of Directors of Leafly Holdings, Inc. (the "Company") appointed Yoko Miyashita, to serve as the Secretary of the Company, effective immediately.
On February 13, 2025, each of Denise Brooks-Williams and Shekar Narasimhan informed Broadstone Net Lease, Inc. (referred to herein as the “Company,” “we,” “our,” or “us”) that they would not stand for re-election as directors of the Company and that the decision not to stand for re-election did not involve any disagreement with the Company.
On February 13, 2025, each of Denise Brooks-Williams and Shekar Narasimhan informed Broadstone Net Lease, Inc. (referred to herein as the “Company,” “we,” “our,” or “us”) that they would not stand for re-election as directors of the Company and that the decision not to stand for re-election did not involve any disagreement with the Company.
On February 13, 2025, the Board appointed Richard Imperiale and Joseph Saffire as directors of the Company, effective as of the same day, to serve until the 2025 Annual Meeting.
On February 13, 2025, the Board appointed Richard Imperiale and Joseph Saffire as directors of the Company, effective as of the same day, to serve until the 2025 Annual Meeting.
On February 17, 2025, our subsidiary, Sirius XM Radio LLC, entered into an Employment Agreement (the “Employment Agreement”) with Richard N. Baer to serve as our new Executive Vice President, General Counsel and Secretary.
On February 13, 2025, Nicole Giles was appointed Chief Accounting Officer of Citigroup Inc. (Citi), effective as of February 21, 2025, and Controller of Citi, effective immediately.
Ms. Giles will replace Robert Walsh, who will step down as Citi’s interim Chief Accounting Officer, effective as of February 21, 2025.
David Fleischman will transition from his current role as Chief Product Officer, effective as of the Effective Date, to serve as Chief Experience Officer of the Company.
Kulesh Shanmugasundaram, Chief Technology Officer of the Company, informed the Company that he will resign from his role, effective as of March 31, 2025
the Company announced that Kris Boon, age 39, was appointed Chief Product Officer of the Company, effective as of March 31, 2025.
On February 14 , 2025, Sandra Leung notified Bristol-Myers Squibb Company (the “Company”) of her intention to retire from her position as Executive Vice President, General Counsel in 2025.
Katrina Sparano retired as the Company’s Chief Financial Officer and Treasurer effective February 15, 2025.
Kaitlyn O’Neil was appointed as the Company’s new Principal Financial Officer and Treasurer, effective such date.
On February 12, 2025, Gary K. Adams and Denise L. Ramos each informed the Board of Directors (the “Board”) of Phillips 66 (the “Company”) of their intent not to stand for reelection to the Board at the Company’s 2025 Annual Meeting of Shareholders (the “Annual Meeting”).
On February 12, 2025, Gary K. Adams and Denise L. Ramos each informed the Board of Directors (the “Board”) of Phillips 66 (the “Company”) of their intent not to stand for reelection to the Board at the Company’s 2025 Annual Meeting of Shareholders (the “Annual Meeting”).
appointed Mr. Oleg Nodelman, Founder and Portfolio Manager of EcoR1 (as defined below), as a director of the Company, effective as of February 17, 2025.
Effective February 13, 2025, Milton H. Werner, Ph.D. resigned as President, Chief Executive Officer and principal executive officer of Inhibikase Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors (the “Board”) of the Company (the “Resignation”).
Effective February 14, 2025, the Board appointed Mark Iwicki as President, Chief Executive Officer and principal executive officer of the Company (the “Appointment”).
James P. Walsh will assume the role of Chief Operating Officer beginning July 1, 2025
Philip Titterton, the Company’s current Chief Operating Officer, will take on an advisory position for the foreseeable future with the Company and assist with special operations projects.
Mr. LaRose became a full-time non-officer employee of the Company, and is expected to remain employed for a transition period ending on April 30, 2025.
appointed Sabrina Simmons to succeed Brian LaRose as the Company’s Chief Financial Officer (the “CFO Succession”), effective as of February 17, 2025
Ms. Simmons resigned from the Board
On February 18, 2025, Norwood Financial Corp (the “Company”) announced that Susan Campfield retired from the Board of Directors of the Company and its wholly-owned subsidiary, Wayne Bank.
On February 14, 2025, the Board appointed Frank Karbe, 56, as the Company’s Chief Financial Officer (including as its principal financial officer and principal accounting officer), effective as of Mr. Karbe’s employment start date, which is expected to be February 24, 2025
On February 12, 2025, Cidara Therapeutics, Inc. (the “Company”) and Preetam Shah, Ph.D., MBA., the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, mutually agreed to Dr. Shah’s separation from such roles with the Company, effective February 24, 2025
On February 12, 2025, John Mazzola notified the Company that he intends to retire from his position as Chief Operating Officer of Vicarious Surgical Inc. (the “Company”), effective April 1, 2025.
On February 18, 2025, Christian Brühlmann resigned from his position as Chief Strategy Officer of the Company.
On February 18, 2025, Robert W. Bourne, Senior Vice President and Chief Commercial Officer of Western Midstream Holdings, LLC (“WES GP”), the general partner of Western Midstream Partners, LP (“WES”), which owns Western Midstream Operating GP, LLC (the “General Partner”), the general partner of Western Midstream Operating, LP (the “Partnership”), entered into a Retirement Agreement and General Release (the “Retirement Agreement”) with WES.
On February 18, 2025, Robert W. Bourne, Senior Vice President and Chief Commercial Officer of Western Midstream Holdings, LLC, the general partner of Western Midstream Partners, LP (“WES”), entered into a Retirement Agreement and General Release (the “Retirement Agreement”) with WES.
the Board of Directors of Consumers Bancorp, Inc. (the “Company”) approved the appointment of David R. Bickerton as a Class I director, effective March 13, 2025.
Mr. Adamson will succeed Jeremy Thigpen, who has led Transocean as Chief Executive Officer since 2015.
subject to shareholder approval at the Company’s 2025 annual general meeting, Mr. Thigpen is expected to be appointed as Executive Chair of the Board of Directors
Mr. Chad Deaton, Transocean’s current Chair of the Board, will transition to Lead Independent Director.
Keelan Adamson, the Company’s President and Chief Operating Officer, will become President and Chief Executive Officer following a transition period, which is expected to conclude during the second quarter of 2025.
The Company also appointed Mr. Tarala to the position of secretary of the Company as of February 12, 2025.
Michael D. Farkas (aged 52) was appointed Chief Executive Officer and Executive Chairman of the Company
Joel Kleiner (aged 36) was appointed Chief Financial Officer of the Company.
Yehuda Levy ceased to be the Company’s Interim Chief Executive Officer.
Effective February 13, 2025, Richard Perez was terminated as Chief Financial Officer of Algorhythm Holdings, Inc.
On February 13, 2025, the Board of Directors (the “Board”) of the Company appointed Alex Andre (age 50) as Chief Financial Officer and General Counsel of the Company.
Mr. Paulsen will now be joining the Company effective March 10, 2025.
On February 15, 2025, Roderick K. West, a member of the Board of Directors (the “Board”) of Essential Utilities, Inc. (the “Company”) since 2023, informed the Company of his resignation as a director and as a member on all Board committees on which he served, effective immediately.
On February 11, 2025, Kathleen S. Pushor notified the Board of Directors (the “Board”) of Insight Enterprises, Inc. (the “Company”) that she intends to retire from the Board and will not stand for election at the Company’s next annual meeting of stockholders (the “2025 Annual Meeting”).
Mr. Breuer is replacing Mr. David E. Constable, who will continue to serve as Executive Chairman of the Board.
the Board of Directors (the “Board”) of Fluor Corporation (the “Corporation”) appointed Mr. James R. Breuer as Chief Executive Office of the Corporation, effective May 1, 2025.
The Company previously announced the appointment of Tom Siragusa as interim chief financial officer, interim principal financial officer and interim principal accounting officer effective February 16, 2025.
the Company and Sergio Cervantes, the Chief Financial Officer of the Company agreed that Mr. Cervantes’ employment would be terminated, effective February 16, 2025
On February 13, 2025, the Board appointed Paul Wierbicki to the Board with immediate effect to fill the vacancy created by Ms. Hilleman’s resignation.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.